InsiderSignal.AI

InsiderSignal.ai

KALV - Kalvista Pharmaceuticals, Inc.

Insider Sale by Piekos Brian (CFO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Piekos Brian, serving as CFO at Kalvista Pharmaceuticals, Inc. (KALV), sold 1,862 shares at $20.22 per share, for a total transaction value of $37,643.00. Following this transaction, Piekos Brian now holds 18,150 shares of KALV.

This sale represents a 9.00% decrease in Piekos Brian's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, April 17, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 20, 2026, 3 days after the trade was made.

Kalvista Pharmaceuticals, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Piekos Brian

CFO

Brian Piekos is the Chief Financial Officer (CFO) of KalVista Pharmaceuticals, Inc. (KALV), a role he assumed recently, bringing over 25 years of financial and strategic planning experience in the biopharmaceutical industry.[[1]](https://www.nasdaq.com/articles/kalvista-pharma-appoints-brian-piekos-new-cfo)[[2]](https://www.kalvista.com/about/senior-management/brian-piekos/) Prior to joining KalVista, he served as CFO at Elicio Therapeutics, where he led the company's launch as a public entity, and held the position of CFO at Gemini Therapeutics, as well as Executive Vice President, CFO, and Treasurer at AMAG Pharmaceuticals.[[1]](https://www.nasdaq.com/articles/kalvista-pharma-appoints-brian-piekos-new-cfo)[[2]](https://www.kalvista.com/about/senior-management/brian-piekos/) Earlier in his career, Piekos occupied leadership roles in corporate finance, tax, and treasury at Cubist Pharmaceuticals, and began as a healthcare investment banker at Needham & Company and Leerink Partners.[[1]](https://www.nasdaq.com/articles/kalvista-pharma-appoints-brian-piekos-new-cfo)[[2]](https://www.kalvista.com/about/senior-management/brian-piekos/) Piekos holds a B.A. in biochemistry from Ithaca College, an M.S. in molecular biology from the University of Massachusetts Medical School, and an MBA from the Simon Business School at the University of Rochester.[[2]](https://www.kalvista.com/about/senior-management/brian-piekos/) As CFO of KalVista, he has engaged in recent insider trading activities, including RSU vesting and share sales for tax withholding.[[3]](https://www.stocktitan.net/sec-filings/KALV/form-4-kal-vista-pharmaceuticals-inc-insider-trading-activity-8b41c27197db.html)

View full insider profile →

Trade Price

$20.22

Quantity

1,862

Total Value

$37,643.00

Shares Owned

18,150

Trade Date

Friday, April 17, 2026

4 days ago

SEC Filing Date

Monday, April 20, 2026

Filed 3 days after trade

HEALTHCAREBIOTECHNOLOGY

About Kalvista Pharmaceuticals, Inc.

Company Overview

No company information available
View news mentioning KALV

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5810447

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime